Skip to main content
Premium Trial:

Request an Annual Quote

FDA Clears Meridian's MDx Test for Group B Strep

NEW YORK (GenomeWeb News) – Meridian Bioscience today announced the US Food and Drug Administration has cleared its molecular diagnostic test for Group B Streptocococcus (GBS).

The clearance is the second for a Meridian MDx test that runs on its illumigene platform, following FDA clearance of the Cincinnati-based firm's test for C.difficile in June 2010.

According to the company, Strep B is a major perinatal pathogen for both mothers and infants, and the GBS test allows laboratories to comply with recommendations from the Centers for Disease Control and Prevention calling for universal culture-based screening to be performed at 35 to 37 weeks of gestation.

The test, Meridian said, has a simplified workflow and increased sensitivity "for early diagnosis and proper management." Using loop-mediated isothermal DNA amplification technology, the GBS test can yield results in less than one hour.

"The new test begins the expansion of the illumigene platform and provides a molecular technology that is affordable, simple, and quick," Richard Eberly, COO of Meridian, said in a statement.

In its fourth-quarter earnings release last month the company said that it plans launches later this year of its illumigene Mycoplasma pneumonia, illumigene Group A Strep, and illumigene Pertussis for whooping cough tests.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.